[Therapeutic use of hemoderivatives].
作者信息
Yurrebaso Eguilior N, Mota Villaplana F M, Montoro Ronsano J B
机构信息
Unidad de Hemofilia-Servicio de Farmacia, Hospital Vall d'Hebrón, Barcelona.
出版信息
Sangre (Barc). 1997 Oct;42(5):423-7.
PMID:9424747
Abstract
摘要
相似文献
1
[Therapeutic use of hemoderivatives].
Sangre (Barc). 1997 Oct;42(5):423-7.
2
[The main characteristics of blood products in current use].[当前使用的血液制品的主要特征]
Rev Prat. 1989 Sep 11;39(20):1745-9.
3
Plasma-derived biological medicines used to promote haemostasis.用于促进止血的血浆源性生物药物。
Thromb Haemost. 2008 May;99(5):851-62. doi: 10.1160/TH07-10-0592.
4
[Traceability of drugs derived from blood: regulation and pharmaco-economic implications after 24 months of application in Paris CHU].
Pathol Biol (Paris). 1997 Nov;45(9):741-50.
5
Current approaches to the preparation of plasma fractions.血浆成分制备的当前方法。
Biotechnology. 1991;19:165-76. doi: 10.1016/b978-0-7506-9120-8.50013-5.
6
Note for guidance. Guidelines for medicinal products derived from human blood and plasma. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.指导说明。人血和血浆衍生药品指南。专利药品委员会：生物技术/药学特设工作组和药品安全工作组。
Biologicals. 1992 Jun;20(2):159-64.
7
[Clinical importance of human plasma proteins and their future development].[人血浆蛋白的临床重要性及其未来发展]
Beitr Infusionsther. 1991;28:115-23.
8
Self-sufficiency--20 years on.
Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 4:S9-14.
9
Factors determining quality of plasma.决定血浆质量的因素。
Vox Sang. 1998;74 Suppl 2:507-11. doi: 10.1111/j.1423-0410.1998.tb05466.x.
10
[Viral safety of hemoderivatives: in search of zero risk].
Sangre (Barc). 1996 Apr;41(2):97-100.
Zotero 插件